Clinical trial · Interventional
Development of a Response Signature to Neoadjuvant Chemotherapy for Breast Cancer
Development of a Response Signature to Neoadjuvant Chemotherapy for Breast
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer is the most frequent cancer in women. It is often treated with neoadjuvant chemotherapy, administered before surgical resection. Unfortunately, many patients do not respond to this treatment, or only respond partially. Clinicians therefore need predictive biomarkers of treatment response. Thanks to an innovative technique, called CATS, this study aims at identifying blood and tissue biomarkers which are predictive of response to chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetic signature | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Retrospective study
- description
- Tumoral tissue of 100 patients with breast cancer treated with neoadjuvant chemotherapy.
- interventionNames
- Genetic: Genetic signature
- type
- OTHER
- label
- Prospective study
- description
- Tumoral tissue and plasma of 120 patients with breast cancer treated with neoadjuvant chemotherapy.
- interventionNames
- Genetic: Genetic signature
Primary outcomes (1)
- measure
- The number of molecular signatures predictive of response to neoadjuvant chemotherapy which would be able to discriminate between patient groups based on their epithelio-mesenchymal transition status and their immune status.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women and men with breast cancer * Treated with neoadjuvant chemotherapy Exclusion Criteria: * None
References
Publications (0)
Data not yet available